The Boehringer Ingelheim group is headquartered in Ingelheim, Germany, and operates globally with 140 affiliates and more than 46,000 employees, making it one of the world’s 20 largest human pharmaceutical research and development businesses.

Through our participation in medical and pharmaceutical research, both in Canada and worldwide, we have contributed to significant improvements in healthcare and developed innovative and cost effective medicines.

We have earned a reputation as a leader in the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD), and have broadened the scope of our work to include diseases such as hypertension, stroke, arthritis, benign prostatic hyperplasia (BPH), Parkinson’s disease and HIV/AIDS.